Zhen-zhou Shen

Shanghai, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology
Published: August 14, 2020

Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.

Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.

Journal: Cancer
Published: October 22, 2018

Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.

Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.

Journal: Breast cancer research : BCR
Published: July 04, 2018

Surgical management of breast cancer in China: A 15-year single-center retrospective study of 18,502 patients.

Surgical management of breast cancer in China: A 15-year single-center retrospective study of 18,502 patients.

Journal: Medicine
Published: November 10, 2016

The association between China's Great famine and risk of breast cancer according to hormone receptor status: a hospital-based study.

The association between China's Great famine and risk of breast cancer according to hormone receptor status: a hospital-based study.

Journal: Breast cancer research and treatment
Published: June 19, 2016

Current status of breast reconstruction in China: an experience of 951 breast reconstructions from a single institute.

Current status of breast reconstruction in China: an experience of 951 breast reconstructions from a single institute.

Journal: Gland surgery
Published: June 14, 2016

Predicting Non-sentinel Lymph Node Metastasis in a Chinese Breast Cancer Population with 1-2 Positive Sentinel Nodes: Development and Assessment of a New Predictive Nomogram.

Predicting Non-sentinel Lymph Node Metastasis in a Chinese Breast Cancer Population with 1-2 Positive Sentinel Nodes: Development and Assessment of a New Predictive Nomogram.

Journal: World journal of surgery
Published: September 02, 2015

Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.

Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.

Journal: Asian Pacific journal of cancer prevention : APJCP
Published: June 25, 2015

Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer.

Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer.

Journal: OncoTargets and therapy
Published: March 14, 2015

Absence of multiple atypical chemokine binders (ACBs) and the presence of VEGF and MMP-9 predict axillary lymph node metastasis in early breast carcinomas.

Absence of multiple atypical chemokine binders (ACBs) and the presence of VEGF and MMP-9 predict axillary lymph node metastasis in early breast carcinomas.

Journal: Medical oncology (Northwood, London, England)
Published: June 08, 2014

ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.

ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.

Journal: PloS one
Published: May 19, 2014

Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.

Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.

Journal: The oncologist
Published: May 03, 2013
Showing 1-12 of 22

Last Updated: 09/26/2026